Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome?

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Current pharmaceutical design

• Publication date

  2012-10-31

• Fields of study

  Medicine

• Identifiers
  DOI 10.2174/138161212803251934PMID 22724420
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.

  2011cited by this paper
• The Effect of St John's Wort on the Pharmacodynamic Response of Clopidogrel in Hyporesponsive Volunteers and Patients: Increased Platelet Inhibition by Enhancement of CYP3A4 Metabolic Activity

  2011cited by this paper
• Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study

  2011cited by this paper
• 2011 ACCF/AHA focused update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in

  2011cited by this paper
• Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease.

  2011cited by this paper
• Paraoxonase-1 is a major determinant of clopidogrel efficacy

  2011cited by this paper
• High on-clopidogrel platelet reactivity: genotyping can help to optimize antiplatelet treatment.

  2011cited by this paper
• High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes.

  2011cited by this paper
• Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype.

  2011cited by this paper
• Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance - The BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy

  2011cited by this paper
• Optimizing of thienopyridine therapy by multiple electrode platelet aggregometry in clopidogrel low responders undergoing PCI

  2011cited by this paper
• Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping.

  2011cited by this paper
• Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention: A Time-Dependent Analysis of the Gauging Responsiveness With a VerifyNow P2Y12 Assay Impact on Thrombosis and Safety (GRAVITAS) Trial

  2011cited by this paper
• Calcium-channel blockers do not alter the clinical efficacy of clopidogrel after myocardial infarction: a nationwide cohort study.

  2011cited by this paper
• Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.

  2011cited by this paper
• High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2).

  2011cited by this paper
• Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.

  2010cited by this paper
• Absorption, Distribution, Metabolism, and Excretion of Ticagrelor in Healthy Subjects

  2010cited by this paper
• Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement

  2010cited by this paper
• The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to cyp 2c19*2 genotype: first experience in patients

  2010cited by this paper
• Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement

  2010cited by this paper
• Clopidogrel with or without omeprazole in coronary artery disease.

  2010cited by this paper
• Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism.

  2010cited by this paper
• Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.

  2010cited by this paper
• Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.

  2010cited by this paper
• Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.

  2010cited by this paper
• First Analysis of the Relation Between CYP2C19 Genotype and Pharmacodynamics in Patients Treated With Ticagrelor Versus Clopidogrel: The ONSET/OFFSET and RESPOND Genotype Studies

  2010cited by this paper
• Guidelines on myocardial revascularization.

  2010cited by this paper
• Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis.

  2009cited by this paper
• Cytochrome p-450 polymorphisms and response to clopidogrel.

  2009cited by this paper
• A Possible Mechanism for the Differences in Efficiency and Variability of Active Metabolite Formation from Thienopyridine Antiplatelet Agents, Prasugrel and Clopidogrel

  2009cited by this paper
• Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis.

  2009cited by this paper
• Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel.

  2009cited by this paper
• Intensifying Platelet Inhibition With Tirofiban in Poor Responders to Aspirin, Clopidogrel, or Both Agents Undergoing Elective Coronary Intervention: Results From the Double-Blind, Prospective, Randomized Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance

  2009cited by this paper
• Ticagrelor versus clopidogrel in patients with acute coronary syndromes.

  2009cited by this paper
• Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.

  2009cited by this paper
• The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease

  2009cited by this paper
• Genetic determinants of response to clopidogrel and cardiovascular events.

  2009cited by this paper
• Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial.

  2009cited by this paper
• Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel

  2009cited by this paper
• Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition

  2009cited by this paper
• Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention.

  2009cited by this paper
• Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention.

  2008cited by this paper
• The association of cigarette smoking with enhanced platelet inhibition by clopidogrel.

  2008cited by this paper
• Functional effects of high clopidogrel maintenance dosing in patients with inadequate platelet inhibition on standard dose treatment.

  2008cited by this paper
• Effects of the Proton Pump Inhibitor Lansoprazole on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel

  2008cited by this paper
• A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days.

  2008cited by this paper
• Immature platelets in patients with acute coronary syndromes

  2008cited by this paper
• Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.

  2008cited by this paper
• Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.

  2008cited by this paper
• Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study.

  2008cited by this paper
• Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease.

  2008cited by this paper
• Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study.

  2008cited by this paper
• Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial.

  2008cited by this paper
• Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study.

  2008cited by this paper
• Calcium channel blockers reduce the antiplatelet effect of clopidogrel

  2008cited by this paper
• Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.

  2008cited by this paper
• Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?

  2007cited by this paper
• The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel’s active metabolite

  2007cited by this paper
• Prasugrel versus clopidogrel in patients with acute coronary syndromes.

  2007cited by this paper
• Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients With Diabetes Mellitus and Coronary Artery Disease: Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) Study

  2007cited by this paper
• Platelet function in clopidogrel-treated patients with acute coronary syndrome

  2007cited by this paper
• The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis

  2007cited by this paper
• Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis.

  2007cited by this paper
• Vasodilator‐stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events

  2007cited by this paper
• The Disposition of Prasugrel, a Novel Thienopyridine, in Humans

  2007cited by this paper
• Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

  2007cited by this paper
• Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention.

  2007cited by this paper
• ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome

  2007cited by this paper
• Platelet activation and atherothrombosis.

  2007cited by this paper
• Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects.

  2006cited by this paper
• A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants

  2006cited by this paper
• Impact of P‐glycoprotein on clopidogrel absorption

  2006cited by this paper
• The obesity paradox in non-ST-segment elevation acute coronary syndromes: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association Guidelines Quality Improvement Ini

  2006cited by this paper
• Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.

  2006cited by this paper
• Variability in platelet responsiveness to clopidogrel among 544 individuals.

  2005cited by this paper
• Low-dose aspirin for the prevention of atherothrombosis.

  2005cited by this paper
• Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment.

  2005cited by this paper
• Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation.

  2005cited by this paper
• Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study.

  2005cited by this paper
• Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases

  2005cited by this paper
• Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study.

  2005cited by this paper
• Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies.

  2005cited by this paper
• Variable extent of clopidogrel responsiveness in patients after coronary stenting

  2004cited by this paper
• Contribution of Hepatic Cytochrome P450 3A4 Metabolic Activity to the Phenomenon of Clopidogrel Resistance

  2004cited by this paper
• Clopidogrel for Coronary Stenting Response Variability, Drug Resistance, and the Effect of Pretreatment Platelet Reactivity

  2003cited by this paper
• Resistance to thienopyridines: Clinical detection of coronary stent thrombosis by monitoring of vasodilator‐stimulated phosphoprotein phosphorylation

  2003cited by this paper
• Atorvastatin Reduces the Ability of Clopidogrel to Inhibit Platelet Aggregation: A New Drug–Drug Interaction

  2003cited by this paper
• Individual variations of platelet inhibition after loading doses of clopidogrel

  2002cited by this paper
• Structure and stereochemistry of the active metabolite of clopidogrel.

  2002cited by this paper
• Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism

  2002cited by this paper
• Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.

  2001cited by this paper
• Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation.

  1999cited by this paper
• A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents.

  1996cited by this paper
• Clinical Experience With the Palmaz‐Schatz Coronary Stent: Initial Results of a Multicenter Study

  1991cited by this paper
• Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion.

  1985cited by this paper

• Genetics in the Clinical Decision of Antiplatelet Treatment.

  2017cites this paper
• Editorial: Paving the way for improved antiplatelet therapy.

  2012cites this paper
• Atherosclerotic coronary artery disease

  2012cites this paper